Clinical Research Directory
Browse clinical research sites, groups, and studies.
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
Sponsor: St. Jude Children's Research Hospital
Summary
The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.
Official title: Pilot Trial of Stimulant Treatment to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
Key Details
Gender
All
Age Range
8 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2025-11-25
Completion Date
2028-08
Last Updated
2026-03-12
Healthy Volunteers
No
Conditions
Interventions
Extended-Release Methylphenidate
Participants will receive a weight-based dose of extended-release methylphenidate (0.6 mg/kg/day), rounded to either 10 mg or 20 mg, taken orally once daily for 4 weeks.
Locations (1)
St. Jude Children's Research Hospital
Memphis, Tennessee, United States